98% Injectable Polypeptide Hormones Eptifibatide Raw Steroid Powders CAS 148031-34-9

98% Injectable Polypeptide Hormones Eptifibatide Raw Steroid Powders CAS 148031-34-9

Basic Info.

Eptifibatide

Sequence: Mpr-Har-Gly-Asp-Trp-Pro-Cys-NH2

Cas No.: 148031-34-9

Molecular Formula: C35H49N11O9S2

Molecular Weight: 831.96

Appearance: White slightly yellwish powder

Specific Rotation[20/D]: -75.0~-95.0°(C=1,1%HAc)

Amino Acids composition: ± 10%

Peptide Purity (By HPLC): >98% by area integration

Related Substance (By HPLC): Total Impurities (%)<2.0%;Largest Single Impurity (%)< 1.0%

Water Content (Karl Fischer): <8.0%

Peptide Content(N determination): >80%

Acetate Content: <15%

IR spectrum: in accordance

Grade : Pharmaceutical Grade

Storage: Closed, below 2 ~ 8ºC preservation

Usage : Platelet glycoprotein receptor antagonist model, the third generation of antiplatelet drugs. For acute coronary syndrome (including unstable angina or non Q wave myocardial infarction) or percutaneous coronary interventional therapy (including angioplasty or atheromatous plaque excision).

Description:

Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class.[1] Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the so-called arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.

Integrilin is sold in two strengths, globally: vials containing 2 mg/ml (20 mg totally) and 0.75 mg/ml (75 mg totally).

Application:

Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI).

The drug is usually applied together with aspirin or clopidogrel and (low molecular weight or unfractionated) heparin. Additionally, the usual supportive treatment consisting of applications of nitrates, beta-blockers, opioid analgesics and/or benzodiazepines should be employed as indicated. Angiographic evaluation and other intensive diagnostic procedures may be considered a first line task before initiating therapy with eptifibatide.